More Articles

Rituximab ‘similar biologic’ shows equivalent efficacy and safety Biosimilars/Research | Posted 02/05/2014

A retrospective analysis of cancer patients who received either originator or ‘similar biologic’ rituximab chemotherapy showed comparable efficacy and safety [1].

Actavis to acquire generics from Akorn Pharma News | Posted 02/05/2014

US generics major Actavis announced on 17 April 2014 that it had made a deal with Akorn and Hi-Tech Pharmacal (Hi-Tech) to buy five of their products.

Biosimilars approved in New Zealand Biosimilars/General | Posted 02/05/2014

Last update: 2 May 2014In New Zealand, the regulatory body for the approval of medicines, including biosimilars, is the New Zealand Medicines and Medical Devices Safety Authority (Medsafe).

UK launches generic medicines forum Generics/General | Posted 02/05/2014

The UK’s drug regulatory agency, the Medicines and Healthcare products Regulatory Agency (MHRA) and the British Generic Manufacturers Association (BGMA) announced on 16 April 2014 the launch of a n...

The generics market in Taiwan Reports | Posted 02/05/2014

Taiwan is a growing market for pharmaceuticals and the generics market is becoming more competitive in terms of price and quality, according to a presentation by Yi-Yun Wang [1].

Challenges for the regulation of biosimilars Biosimilars/Research | Posted 25/04/2014

The European Medicines Agency (EMA) was the first agency to issue guidelines for the approval of biosimilars via an abbreviated registration process back in 2006. Since then the agency has develope...

Rituximab non-originator biological approved in Russia Biosimilars/News | Posted 25/04/2014

Russian biotechnology company Biocad announced on 17 April 2014 that the Russian Ministry of Health has approved the company’s rituximab non-originator biological, AcellBia (BCD-020). The drug is a...

Free samples increase use of branded drugs Generics/Research | Posted 25/04/2014

The practice of giving free samples to physicians to give out to their patients increases the use of brand-name drugs, according to research published in JAMA Dermatology [1].